Gold compounds and pharmaceutically acceptable salts thereof are disclosed. Certain compounds and salts are active as antibacterial, antifungal, and/or anti-parasitic agents. The disclosure provides pharmaceutical compositions containing the gold compounds. Methods of using the gold compounds to treat bacterial infections are disclosed.

Disclosed herein, inter alia, are prodrug compositions and methods of using the same for treatment and detection of disease. Specifically, disclosed herein is a compound of formula (I) having spiro-fused 1,2,4-trioxolane and piperidine rings, namely, 1,2,4-trioxa-8-azaspiro[4.5] decane. Also disclosed is a pharmaceutical composition containing the compound and a pharmaceutically acceptable carrier. ##STR00001##

Disclosed herein, inter alia, are prodrug compositions and methods of using the same for treatment and detection of disease. Specifically, disclosed herein is a compound of formula (I) having spiro-fused 1,2,4-trioxolane and piperidine rings, namely, 1,2,4-trioxa-8-azaspiro[4.5] decane. Also disclosed is a pharmaceutical composition containing the compound and a pharmaceutically acceptable carrier. ##STR00001##

The present invention relates to an iron chelator combination, more specifically a combination of a non-iron metal-desferrioxamine B complex and an additional iron chelator, for preventing, inhibiting, reducing or ameliorating iron overload or elevated levels of labile iron.

The present invention relates to an iron chelator combination, more specifically a combination of a non-iron metal-desferrioxamine B complex and an additional iron chelator, for preventing, inhibiting, reducing or ameliorating iron overload or elevated levels of labile iron.

The present invention relates to methods for treating or preventing atherosclerotic cardiovascular disease and other conditions associated with elevated levels of lipoprotein (a) (Lp(a)) using RNAi constructs targeting the LPA gene, which encodes apolipoprotein(a), a component of Lp(a) particles. In particular, the present invention relates to methods for reducing serum Lp(a) levels and reducing the risk of cardiovascular events in patients with elevated levels of Lp(a) comprising administering an LPA-targeted RNAi construct according to specific dosage regimens. Pharmaceutical compositions comprising the LPA-targeted RNAi constructs for use in the methods are also disclosed.

The disclosure provides a selective inhibitor of DNA-binding to poly (ADP-ribose) polymerase 1 (PARP1), or a pharmaceutically acceptable salt or solvate thereof, for use in treating, ameliorating or preventing cancer. The treatment may be given to a subject suffering from or at risk of osteoporosis or a subject requiring a long-term therapy.

The disclosure provides a selective inhibitor of DNA-binding to poly (ADP-ribose) polymerase 1 (PARP1), or a pharmaceutically acceptable salt or solvate thereof, for use in treating, ameliorating or preventing cancer. The treatment may be given to a subject suffering from or at risk of osteoporosis or a subject requiring a long-term therapy.

The present invention provides inhibitors of thioredoxin reductase, in particular selenium compromised thioredoxin reductase-derived apoptotic protein (SecTRAP) forming agents, for use in treating an immune cell infiltrated cancer (e.g. a T-cell infiltrated cancer) in a subject, wherein said agents stimulate an anti-cancer immune response. The present invention also provides combinations comprising a SecTRAP forming agent and other therapeutic agents for use in treating cancer.

The present invention provides inhibitors of thioredoxin reductase, in particular selenium compromised thioredoxin reductase-derived apoptotic protein (SecTRAP) forming agents, for use in treating an immune cell infiltrated cancer (e.g. a T-cell infiltrated cancer) in a subject, wherein said agents stimulate an anti-cancer immune response. The present invention also provides combinations comprising a SecTRAP forming agent and other therapeutic agents for use in treating cancer.